Anand Patel to Humans
This is a "connection" page, showing publications Anand Patel has written about Humans.
Connection Strength
0.568
-
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
Score: 0.032
-
Novel Therapies in Myelodysplastic Syndrome: Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in? Cancer J. 2023 May-Jun 01; 29(3):188-194.
Score: 0.030
-
Targeted Therapy for MPNs: Going Beyond JAK Inhibitors. Curr Hematol Malig Rep. 2023 06; 18(3):41-55.
Score: 0.030
-
SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It. Clin Lymphoma Myeloma Leuk. 2023 05; 23(5):303-309.
Score: 0.030
-
The Cup Runneth Over: Treatment Strategies for Newly Diagnosed Acute Myeloid Leukemia. JCO Oncol Pract. 2023 02; 19(2):74-85.
Score: 0.029
-
Outcomes After Retreatment With Inotuzumab Ozogamicin for Relapsed/Refractory Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia. JCO Precis Oncol. 2022 10; 6:e2200353.
Score: 0.029
-
Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy. Blood Adv. 2021 10 26; 5(20):4140-4148.
Score: 0.027
-
Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies. Blood Adv. 2021 04 27; 5(8):2264-2271.
Score: 0.026
-
Paraneoplastic Thrombocytopenia. Am J Med. 2021 08; 134(8):976-979.
Score: 0.026
-
Genomics of MPN progression. Hematology Am Soc Hematol Educ Program. 2020 12 04; 2020(1):440-449.
Score: 0.026
-
The Next Generation of JAK Inhibitors: an Update on Fedratinib, Momelotonib, and Pacritinib. Curr Hematol Malig Rep. 2020 12; 15(6):409-418.
Score: 0.026
-
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults. Curr Treat Options Oncol. 2020 05 28; 21(7):57.
Score: 0.025
-
Clinical and Biological Prognostic Factors in Follicular Lymphoma. Hematol Oncol Clin North Am. 2020 08; 34(4):647-662.
Score: 0.025
-
Clinical outcomes of IDH2-mutated advanced-phase Ph-negative myeloproliferative neoplasms treated with enasidenib. Br J Haematol. 2020 07; 190(1):e48-e51.
Score: 0.025
-
Use, variability, and justification of eligibility criteria for phase II and III clinical trials in acute leukemia. Haematologica. 2024 Apr 01; 109(4):1046-1052.
Score: 0.008
-
Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood Cancer J. 2024 02 20; 14(1):32.
Score: 0.008
-
Measurable residual disease conversion rate with consolidation chemotherapy in acute myeloid leukemia. Leuk Lymphoma. 2024 Jan; 65(1):69-77.
Score: 0.008
-
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
Score: 0.008
-
Trans-vaccenic acid reprograms CD8+ T cells and anti-tumour immunity. Nature. 2023 Nov; 623(7989):1034-1043.
Score: 0.008
-
Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia. Blood Adv. 2023 11 14; 7(21):6492-6505.
Score: 0.008
-
Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia. Clin Cancer Res. 2023 08 15; 29(16):3151-3161.
Score: 0.008
-
Clinical and molecular response of acute myeloid leukemia harboring non-canonical FLT3 N676K driver mutations to contemporary FLT3 inhibitors. Haematologica. 2023 08 01; 108(8):2234-2239.
Score: 0.008
-
Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Leukemia. 2023 04; 37(4):799-806.
Score: 0.007
-
Disparities in receiving disease-directed therapy, allogeneic stem cell transplantation in non-Hispanic Black patients with TP53-mutated acute myeloid leukemia. Cancer. 2023 03 15; 129(6):934-945.
Score: 0.007
-
Structural racism is a mediator of disparities in acute myeloid leukemia outcomes. Blood. 2022 04 07; 139(14):2212-2226.
Score: 0.007
-
Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022 07; 97(7):E232-E235.
Score: 0.007
-
Over the Threshold: an Exercise in Clinical Reasoning. J Gen Intern Med. 2022 04; 37(5):1290-1294.
Score: 0.007
-
Provider-Level Barriers to Human Papillomavirus Vaccination in Survivors of Childhood and Young Adult Cancers. J Adolesc Young Adult Oncol. 2022 06; 11(3):284-289.
Score: 0.007
-
The Phantom Menace: Immunodeficiency-Associated Disease in an Immunocompetent Patient. Am J Med. 2021 12; 134(12):1555-1557.
Score: 0.007
-
Impact of race on outcomes in intermediate-risk acute myeloid leukemia. Cancer Causes Control. 2021 Jul; 32(7):705-712.
Score: 0.007
-
Multi-institutional study evaluating clinical outcome with allogeneic hematopoietic stem cell transplantation after blinatumomab in patients with B-cell acute lymphoblastic leukemia: real-world data. Bone Marrow Transplant. 2021 08; 56(8):1998-2004.
Score: 0.007
-
Left Out in the Cold. J Hosp Med. 2021 02; 16(2):105-108.
Score: 0.006
-
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 04 01; 127(7):1039-1048.
Score: 0.006
-
Diagnosis and treatment of mixed phenotype (T-myeloid/lymphoid) acute leukemia with novel ETV6-FGFR2 rearrangement. Blood Adv. 2020 10 13; 4(19):4924-4928.
Score: 0.006
-
The genealogy of teaching clinical reasoning and diagnostic skill: the GEL Study. Diagnosis (Berl). 2020 08 27; 7(3):197-203.
Score: 0.006
-
Peabody's Paradox: Balancing Patient Care and Medical Education in a Pandemic. J Grad Med Educ. 2020 Jun; 12(3):264-268.
Score: 0.006
-
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomab. Blood Adv. 2020 05 26; 4(10):2308-2316.
Score: 0.006
-
The Socrates Project for Difficult Diagnosis at Northwestern Medicine. J Hosp Med. 2020 02 01; 15(2):116-118.
Score: 0.006
-
FOXM1 contributes to treatment failure in acute myeloid leukemia. JCI Insight. 2018 08 09; 3(15).
Score: 0.005
-
Insight into Sweet's syndrome and associated-malignancy: a review of the current literature. Int J Oncol. 2013 May; 42(5):1516-22.
Score: 0.004
-
Sequence requirements for combinatorial recognition of histone H3 by the MRG15 and Pf1 subunits of the Rpd3S/Sin3S corepressor complex. J Mol Biol. 2012 Sep 28; 422(4):519-31.
Score: 0.004